| CAS NO: | 932730-52-4 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| Cas No. | 932730-52-4 |
| 别名 | CDDO-Trifluoethyl Amide,RTA 404,TP-500 |
| 化学名 | 2-cyano-3,12-dioxo-N-(2,2,2-trifluoroethyl)-oleana-1,9(11)-dien-28-amide |
| Canonical SMILES | CC1(CC[C@@]2(CC[C@@](C)([C@@]3(CC[C@]4(C(C)(C(C(C#N)=C[C@@]4(C3=CC5=O)C)=O)C)[H])C)[C@]5([C@@]2(C1)[H])[H])C(NCC(F)(F)F)=O)C |
| 分子式 | C33H43F3N2O3 |
| 分子量 | 572.7 |
| 溶解度 | ≤5mg/ml in ethanol;5mg/ml in DMSO;5mg/ml in dimethyl formamide |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | CDDO-trifluoroethyl-amide (CDDO-TFEA), a trifluoroethylamide derivative of CDDO, is an Nrf2/ARE pathway activator [1][2][3]. The NF-E2-related factor-2 (Nrf2)/antioxidant response element (ARE) signaling pathway is an important pathway involved in antioxidant and anti-inflammatory responses. Modulation of the Nrf2/ARE pathway is an attractive therapeutic target for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD) [2][3]. CDDO-TFEA is an Nrf2/ARE pathway activator. In NSC-34 G93A SOD1 cells, CDDO-TFEA upregulated Nrf2 expression and caused translocation of Nrf2 into the nucleus. CDDO-TFEA also increased the expression of Nrf2/ARE-regulated proteins (NQO-1, HO-1 and Glutathione reductase). In mice with experimental autoimmune encephalomyelitis (EAE), CDDO-TFEA reduced immune and inflammatory cell populations. CDDO-TFEA also significantly reduced Th1 and Th17 cytokines (IL6, IL17, IFNγ, TNFα and GMCSF) [1]. In ALS mice model, CDDO-TFEA upregulated the expression and resulted in translocation of Nrf2 to the nucleus of neurons in the spinal cord. In G93A SOD1 mice, CDDO-TFEA increased the life-span by 17.6 days [2]. References: |
m.cnreagent.com